Try our Advanced Search for more refined results
Life Sciences - May, 2016
332 articles
- FDA Asks Teva For More Info On New Huntington's Drug
- Doctors Denied Early Win In Botox Action Against Allergan
- Pharma Co. Lawsuit Over FDA Threats Premature, Judge Says
- Attorney Web Bios: The Good, The Bad And The Ugly
- DC Circ. Revives Suit Over $325M Czech Arbitration Award
- Valeant Faces RICO Suit In 'Secret' Pharmacy Network Row
- Homeopathics Buyers Can't Change Trial Terms, Boiron Says
- Robbins Geller Will Lead Valeant Securities Fraud Suit
- FDA Warning Wire: Horizon Air, Spiders, Falsified Data
- Deals Rumor Mill: Carmila, Valeant, Bank of America
- Sun Pharma Unit Supoenaed In DOJ Generics Antitrust Probe
- Walgreens Dragged Into Theranos' Faulty Blood Tests Fight
- SV Life Sciences Raises $273.5M For Planned $400M Fund
- Wash. Medicaid Ordered To Cover Expensive Hep C Drugs
- Supreme Court Won't Hear Cubicin Patent Appeal
- Cooley, Kirkland Lead $1.5B Jazz Pharma Deal For Celator
- FDA And Digital Health: Time For A Cultural Exchange
- Neovasc Ducks Mass. Law Claim In Medical Device IP Suit
- 5 Signs You'll Never Excel In BigLaw
- Gibson Dunn DQ Shows Danger Of Handling Privileged Emails
- Chelsea Therapeutics Settles Investor Class Action For $5.5M
- Merrill Lynch, Citi Hit In Class Action Over Cancer Co. IPO
- Lipitor Retailers Push 3rd Circ. To Revive Pay-For-Delay Claims
- Abbott Pushes To Exclude Depakote Testimony On Eve Of Trial
- Behind The Curtain: Technical Advisers In Complex Cases
- Medical Device Co. Says IP Suit Triggers Defamation Policy
- FDA Delays Approval Of AstraZeneca Unit's Potassium Drug
- Takeaways From Chelsea Therapeutics Post-Closing Action
- Driven By Abstraction: Flaws In USPTO, Court 101 Analyses
- GOP Reps Chide HHS On Off-Label Marketing, Urge Changes
- Bayer Tops Pharma Reputation Report, Pfizer At Bottom
- Another Customer Hits Theranos With Blood Test Rip-Off Suit
- JPML Skeptical Of Consolidating Heart Med Suits
- J&J Seeks To Pause Hip Implant Trials After $502M Verdict
- Quinn Emanuel's New Zurich Office To Focus On Disputes
- KaloBios Seeks To Award Board Members For Saving Business
- FDA OKs Buprenorphine Implant To Treat Opioid Addiction
- Pols Wants Answers On Colombian Drug Licensing Policy
- FDA Inaction On Shellfish Petition Dangerous, Suit Alleges
- How To Prepare Your Employees For Litigation Discovery
- 5 Tips For Negotiating And Drafting Joint E-Discovery Plans
- Genetically Modifying Mosquitoes Could Stem Spread Of Zika
- Theranos' Faulty Blood Tests Ripped Off Patients, Suit Says
- Patent Board Kills 3 Ariosa Re-Exams Of Illumina Patent
- Europe Floats Proposal On Drug Cooperation In TTIP
- Class Attys Want OK Of $1B Deal To End Vioxx Marketing Row
- Sanofi Tries To Boot Medivation Board In $9.3B Hostile Bid
- Sanofi Wants Jury Verdict Axed In Amgen Drug Patent Row
- Fed. Circ. Won't Rehear IP Row Over Container Patent
- AstraZeneca Says Del. Order Ends Dr. Reddy's NJ Nexium Suit
- Senju Settles Out Of Apotex's Pinkeye Meds Antitrust Suit
- Pfizer Beats FCA Suit Over Geodon Marketing
- Costco Drops Antitrust Suit Against J&J Over Contact Lenses
- Generic Drugmaker Wins Review Of UCB's Vimpat Patent
- Calif., Wash. Hit J&J With State Lawsuits Over Pelvic Mesh
- Merck Investors Fight For American Pipe Tolling At 3rd Circ.
- PTAB Won't Review Suboxone IP After Teva Misses Deadline
- Bayer Rips Probiotic Class's Use Of 'Rhetoric, Not Evidence'
- FDA Warning Wire: Suspect Data, Bakery Bugs, Faulty Tests
- Fenwick To Launch NYC Office With West Coast Partners
- Medtronic Can't Shake FCA Kickback Claims
- Green Lights Ahead For Medical Pot Legal Work In Pa.
- Stock Tipper Blasts SEC's Newman Stance In 3rd Circ.
- OrbiMed Nets $307M For Israel Health Care Fund
- 1st Circ. Keeps Alive One Claim In Genzyme Drug Dispute
- An FCA Update As We Await High Court's Escobar Decision
- Monsanto Snubs Bayer's $62B Buyout Offer
- Calif. Asbestos Case Opens Door For Shaky Expert Opinions
- Panama Papers: Reminders About Law Firm Cybersecurity
- High Court Urged To Deny Review Of Nixed DNA-Test Patent
- Bayer's $62B Monsanto Bid Would Break Industry Record
- Reed Smith In Houston Snags Antitrust Pro From K&L Gates
- Medtronic, Ex-Sales Rep Settle Alleged Retaliation Suit
- Deals Rumor Mill: Anthem, Teva, SF Holdings
- GOP Unveils New Tactics To Reform ACA Programs
- Oil Explorer, Biotech Junk IPOs Amid Bumpy Market
- Reed Smith Widow Says Expert Was Cleared In Patient Suicide
- Ex-Stryker Salesman Appeals Sanctions To 6th Circ.
- Kyle Bass Convinces PTAB To Review Citius Drug Patent
- 4th Circ. Won't Rehear Bayer's Trademark Case Over Flanax
- Bayer Confirms $62B Offer For Monsanto
- In Congress: Defense Bill, TSCA Reform, Authority Over DC
- Jailed Stock Scheme Atty Says Gov't Misconduct Tainted Case
- Chelsea Shareholders Lose Suit Over Drugmaker's Sale
- Health Hires: K&L Gates, Norton Rose Get Health, IP Attys
- Long Beach Hits Monsanto, Pfizer Unit With Enviro Suit
- Bayer-Monsanto Deal Would Be Tough Sell For Regulators
- Ex-Gilead Recruiter's Atty Defends Use Of Settlement Details
- Actos Buyers Press 2nd Circ. To Revive Antitrust Claims
- Generic-Drug Price-Fixing Suits Belong In Pa., JPML Told
- Supplement Co. Dials Back Promos To End FTC False Ad Suit
- OPINION: Sotomayor's Solution To Pro Bono Is Incomplete
- Creating Barclay Damon: Lessons From A Law Firm Merger
- Tyco Says $60M Drug Heist Trial Win Should Stand
- Myriad Genetics Hit With HIPAA Complaint Over Gene Data
- $13B Salix-Valeant Merger Row Tossed In Del. Chancery
- Neovasc Hit With $70M Verdict In IP, Trade Secrets Trial
- Reflecting On The 20th Anniversary Of BMW V. Gore
- Boutique Tabet DiVito Snags Patent Atty From Katten Muchin
- Fed. Circ. Affirms Denial Of Fees For Dropped Patent Suit
- Probiotic Maker Denies Lying About Sigma, VSL Products
- Fed. Circ. Urged Not To Rehear Generics Jurisdiction Ruling
- Eisai Asks 3rd Circ. To Rehear Lovenox Antitrust Suit
- Deals Rumor Mill: Onex, Sensus USA, Yum Brands
- Bellwether Trials In Doubt After Another Zimmer MDL Setback
- USPTO To Evaluate Eligibility, Obviousness Rejections
- Nexium Pay-For-Delay Trial Needs Redo, Buyers Tell 1st Circ.
- Actavis, Others Can't Yet Market Generic Nucynta, Judge Says
- Attys Scratch Heads As FDA Punts Generic-Label Rule To 2017
- Corporate Counsel: Consumer Becomes Provider (The Sequel)
- Theranos Admits More Than 10K Test Results Were Erroneous
- Judge Says Turing Concedes Liability In Impax AIDS Drug Row
- Still Some Gaps In FDA 3-D Printed Medical Device Guidance
- Judge Posner Slams Courts' Use Of 'Stale, Opaque' Jargon
- Tenn. Health Group Says Clinic Wasn't Agent In Meningitis MDL
- Supplement Co. Asks 9th Circ. For Rehearing In False Ad Suit
- Biopharm Co. To Repay Lender $4M In Ch. 11 Collateral Row
- Settlement Floated In Investor Suit Over Cornerstone Buyout
- House OKs $622M Zika Bill That Dems Say Won't Stop Virus
- Nexium Buyers Defend New Trial Bid In Pay-For-Delay Suit
- Takeda's Suit Targeting Rival Gout Drug Is Dismissed
- B. Braun Admits Tainted Syringe Sales In $7.8M Settlement
- Deals Rumor Mill: Monsanto, Goldman, Hotel Lotte
- Medtronic Drops $350M On Smith & Nephew Gynecology Unit
- No New Trial For Abbott Whistleblower In $219M Stent Row
- Janssen Diabetes Drugs Linked To Amputations, FDA Says
- 5th Circ. Axes Testimony Behind Light Therapy Defect Verdict
- Ex-Warner Chilcott Exec Wants Recordings Barred From Trial
- High Court Is Lost In The Woods With The Laws Of Nature
- Jury Rules Bayer Unit Didn't Copy Foot Care Rival's Marks
- Uptick In FCPA Enforcement Suggests 2015 Drop Was Outlier
- Gilead Fights $50M Bonus Demand After EU Cancer Drug OK
- FDA Warning Wire: Issues At Plant Linked To Listeria
- FDA Rebuked For Blocking Cancer Patient's Treatment
- CVS Tells 1st Circ. Disclaimer Sinks Vitamin E Label Fight
- Coherus Scores Review Of An AbbVie Humira Patent
- Dr. Scholl's Foot Care Logo Dispute Now Up To Jury
- Novartis Splits Pharma Biz In Two, Parts With Drug Exec
- Deals Rumor Mill: Asahi Group, Investcorp, Valeant
- Baxter Infusion Pump Patents Survive Alice Challenge
- 2nd Circ. Affirms Dismissal Of Lipitor Off-Label Marketing Suit
- GSK, Teva Press High Court To Hear Lamictal Case
- OPINION: Stop 'Vigorously Defending' Your Clients
- Vague Claims, Immunity Doom Painkiller Data Suit, UC Says
- The Myth Of 'Price Disconnects' In US Pharma Markets
- Supplement Co. Seeks End To 'Gamesmanship' In Label Suit
- 2nd Circ. Urged To Adopt Octane Fitness In Trademark Cases
- Thermo Fisher To Pay $35M In Enzo DNA Patent Row
- 2nd Circ. Tosses Apotex's False Ad Row Over MS Drug
- IMS Health Investor Seeks To Halt $9B Quintiles Merger
- Valeant Expands Drug Discount Program After Price Increases
- Fed. Circ. Rules Glenmark Infringed Bayer's Finacea Patent
- PE-Backed Cos., Biotech Prime 3 IPOs Totaling $439M
- Cubist Asks High Court To Review Nixing Of Cubicin Patents
- Wachtell Guides Pfizer's $5.2B Anacor Deal
- A Look At USPTO's New Patent-Eligibility Examples
- The Top 100 Firms For Minority Attorneys
- The Top 50 Firms For Minority Equity Partners
- White & Case Outpacing Peers In Diversity
- US Law Firms Fail To Move Needle On Racial Diversity
- The 5 Ways BigLaw Is Failing Minorities
- Split 6th Circ. Clears Abbott In FCA Suit Alleging Bribe
- Lab's Insurer Ducks Coverage For Suit Over Dead Horses
- Jazz Makes Deal In Xyrem IP Fight With Ranbaxy, Sun, Ohm
- City Sues Allergan, Mylan, Others Over Generic Price Hikes
- Fed. Circ. Says Merck Patent Nixed By On-Sale Bar
- J&J Unit Settles Its Patent Suit Over Glucose Testing Strip
- 6 Firms Steer 4 IPOs Totaling $937M Led By Blank Check Deal
- Amgen Lobs Patent Suit At Sandoz's Neulasta Biosimilar
- Pfizer Drugs Can't Be Used For Executions Anymore
- House Passes Comprehensive Anti-Opioid Abuse Bill
- Deals Rumor Mill: Teva, ConvaTec, Abraaj
- Sanofi Says Evidence Doesn't Justify Verdict In Patent Suit
- AIDS Group Agrees To Drop 2 Cos. From Drug Antitrust Row
- Taxation With Representation: Weil, Skadden, Morrison Cohen
- Cravath Guides Mylan In Up To $1B Deal For Pharma Biz
- False Ad Row Over Homeopathic Label Moves Closer To Trial
- 23andMe Says Insurer Must Cover Suit Over Test Accuracy
- 5 Ways To Avoid Obviousness-Type Double Patenting
- Half Of Workstation's Patent Claims Obvious, PTAB Rules
- Fed. Circ. OKs Use Of Local Patent Rule To Nix Stryker Case
- KaloBios Must Make Decision On Drug Trials, Hospital Says
- US Urges High Court To Review Fed. Circ. Life Tech Ruling
- 23andMe Can't Arbitrate False Ad Suits, 9th Circ. Told
- FDA Orders Stronger Warning Labels For Antibiotic Class
- Fresenius Gets PTAB To Deal Another Blow On Cubicin Patents
- Deals Rumor Mill: SingTel, Bayer, Bosch
- Fried Frank Adds Ex-Reed Smith Atty To M&A Practice
- Sanofi Wins Temporary Reprieve From Kickbacks Action
- Norton Rose Adds Gowling Corporate Partner In Toronto
- Records To Be Unsealed From Ky. OxyContin Suit
- Flintstones Gummy Buyers Seek Cert. In Suit Against Bayer
- Food Co. Sues Commerce For Bungled Customs Instructions
- Aegerion To Admit Guilt, Pay $40M Over Drug Marketing
- Corporate Counsel: Consumer Becomes Provider
- New PTAB Chief Judge Hailed For Patent Prowess
- Genentech Asks For Sanctions In Kadcyla Patent Suit
- Merck, Genentech Sold Unapproved Drugs, FCA Suit Says
- House Passes New Hurdles For Opioid Drug Approvals At FDA
- FDA Eyes New Fees For Makers Of Over-The-Counter Drugs
- FDA Warns Antipsychotic Drug Can Cause Severe Skin Rash
- Genzyme, Sanofi's Cancer Drug Patent Ruled Valid
- $54M Tobacco IPO Misses Mark, Biotech Curtails Debut
- Colo. Pot Dispensary Fights IRS Over Uprooted Deductions
- Supplement Co. Says Rival's Protein Quality Claims Are False
- Pa. Appeals Court Upholds $3M Verdict In J&J Topamax Case
- What Do The Highest-Paid Lawyers Make An Hour?
- Medtronic Patent Exec Named PTAB Chief Judge
- Allergan Faces Hydrocortisone Antitrust Probe In UK
- USPTO Memo Leaves Eligibility Questions Unanswered
- Recovery Claims: A New Source Of University Funding
- Dr. Scholl's Copied Rival Foot Care Co.'s Logo, Jury Told
- J&J, Merck, Endo Probed Over Pharmacy Benefit Managers
- Express Scripts Looks To Deep-Six Pharmacy Antitrust Claims
- E-Cig Co. Nicopure Sues FDA To Block New Oversight
- Loestrin Buyers Allege Product-Hopping By Warner Chilcott
- Deals Rumor Mill: ABF, Telecom Italia, Pershing Square
- PharMerica Says Public Disclosure Testimony Sinks FCA Suit
- House Passes Five Bills To Curb Opioid Abuse
- Fed. Circ. Backs Medtronic Win In Heart Valve Patent Review
- $2.5M Philly Risperdal Verdict Against J&J Will Stay Put
- FDA Warning Wire: 'Deep Concerns' Prompt Rare Recall Action
- Hospitals Can't Blame Gov't In Meningitis MDL, Judge Told
- Feds Seek $3.7M In Unpaid Fees From Fla. Tobacco Importer
- 'Flanax' Ruling Driven By 'Ethical Outrage,' Drug Co. Says
- 4 Steps To Effective FCPA Acquisition Due Diligence
- Endo, Impax Can't Trim Opana Pay-For-Delay MDL, Class Says
- Genentech Facing Class Action Over Cancer Drug Skimping
- K&L Gates Adds IP Partner From DLA Piper In Australia
- Colo.-Based Marijuana Biz Law Firm Expands Into Fla.
- Sex Supplement Buyer Pushes For Cert. In False Ad Suit
- Pfizer Ducks State Law Label Claims In Lipitor MDL
- Loeb OK'd To Drop Client Suing Ex-IP Atty Over Secrets
- Fed. Circ. Stresses PTAB Rules In Affirming DNA Patent Ruling
- How To Turn Nonbillable Work Into Big Bucks
- Tenn. Hospitals Want Discovery Stays Lifted In Meningitis MDL
- Fed. Circ. Affirms Tossing Of Monitoring Patent Under Alice
- Docs, Drugmakers Call Medicare Pay Experiment Unlawful
- Vitamin Health Not Covered For False Ad Suit, Court Says
- Only Public Sales Trigger AIA On-Sale Bar, USPTO Says
- PharMerica Off The Hook For Successor Liability In FCA Suit
- Health Care Funds Push For Class Cert. In Celexa Drug MDL
- Biotech Cos. Face Pressure To Disclose
- Deals Rumor Mill: Medivation, Triton, Cinven
- Gilead Says Secret Info Being Used By Atty In Harassment Suit
- Abbott Whistleblower Seeks New Trial In $219M Stent Row
- Biolitec Can't Re-Litigate $70M Contempt Order, 1st Circ. Says
- Boston Scientific, Cook Medical Face Vein-Filter Suits
- USPTO Patent Guidelines Give Hope To Life Sciences Cos.
- Investors Say Greatbatch Lied About Stock Incentive Plan
- Del. Judge OKs KaloBios Ch. 11 Disclosure, Investor Pact
- Endo Hits Impax With $100M Suit Over Painkiller IP Agreement
- Fed. Circ. Backs Acacia Unit's PTAB Loss Over Stent Patent
- SEC Says Water Purifier CEO May Have Clean Hands After All
- Health Hires: Wilson Sonsini Gets Bump In M&A, Cooley In IP
- GNC Says Pa. Investor Suit Fatally Relies On Ore. AG Action
- BTG Buying US Oncology Products Maker In $110M Deal
- GSK Rips New Trial Bid From Alleged Paxil Birth Defect Victim
- Deals Rumor Mill: Teva, Colony Capital, Riverstone Holdings
- Intercept To Pay $55M To End Investors' Stock-Drop MDL
- Takeda Says 2nd Circ. Shouldn't Revive Actos Antitrust Row
- The Fastest Rocket Docket For The 8th Straight Year
- Intellia's $108M IPO Leads Pair Of Biotech Floats
- 3rd Circ. Urged To Revive Label Suit Against Novartis
- Medtronic Says Guidant Could Be Liable For Patent Row Fees
- Insurance Coverage Implications Of The J&J Talc Verdicts
- Herbalife Says FTC Talks 'Advanced,' $200M Deal Possible
- USPTO Calls For Clearer Alice Rejections, Aiding Applicants
- Daiichi Sankyo Wins $385M From Ranbaxy's Ex-Owners
- Shkreli Associate Says He Was Cut Out Of $8M KaloBios Pact
- Quest, Contractor Reach Settlement In $90M Debt Dispute
- Actavis Continues Fight For Generic Lialda At Fed. Circ.
- House Democrats Push For $600M To Fight Opioid Abuse
- Amended Sobriety Test Patent Still Nothing New, PTAB Says
- FTC Approves $2.2B Hikma Deal, Pending Divestitures
- Insurer Must Cover Hernia Mesh Trade Secret Row, Court Told
- Express Scripts Hid Risk of Losing Major Client, Investors Say
- High Court Likely To Look At Scope Of US Patent Law Abroad
- Hospira To Fed. Circ.: Don't Alter On-Sale Rule For Patents
- Biomedical Orthopedic Implant Patent Survives AIA Review
- 6 Ways Lawyers Can Enhance Cross-Office Communication
- Peregrine Knew Cancer Drug Trials Were Bunk, 9th Circ. Told
- 8th Circ. Boosts TCPA Class Cert. Bids In Medtox Ruling
- Pfizer Cools To Tax Inversion After Nixed Allergan Deal
- Bayer Wants All Mirena IUD Cases Tossed For Lack Of Experts
- Del. Action Against CytRx Stayed Pending Calif. Court Deals
- Lilly, Canada Clash On NAFTA Filings In $388M Patent Fight
- Fed. Circ. Skeptical Becton Dickinson Patent Survives Alice
- J&J's Talcum Trial Losses Create Litigation Powder Keg
- Fed. Circ. Won't Rehear Ruling That Axed 4 OxyContin Patents
- Deals Rumor Mill: Pfizer, Hellman & Friedman, Carlyle
- Sonova Inks $955M Deal For Hearing Aid Retailer AudioNova
- Colgate Faces New False Ad Suit Over Tooth Whitening Claims
- Fed. Circ. Urged To Rehear Jurisdiction Ruling On Generics
- 3rd Circ. Rejects Lovenox Antitrust Suit Against Sanofi
- Fed. Circ. Could Ease On-Sale Bar Threat To Pharma Patents
- What Is Your Squirm Factor?
- Scalia's Vacancy Shifts High Court On Class Actions
- Valeant — A Case Study In Rotten Culture And Business Ethics
- Paul Weiss Snags Dechert Partner, Ex-Philip Morris GC
- Supplement Sellers Pay FTC $9.2M For Deceiving Consumers
- Supplement Buyers Fight To Keep Class Cert. In False Ad Suit
- Rulings Clear Up Controversy Over Fla. Medical Pot License
- FCA Penalties Set To Double, Raising Fears Of Excess Fines
- Big-Ticket Pharma Plays Help 2 Law Firms Dominate April M&A
- FDA Warning Wire: Cancer Treatment Co. Again Under Fire
- WilmerHale Lures 2 Corporate Attys From White & Case
- Mylan Wins PTAB Review Of Diabetes Drug In Rare Rehearing
- Acacia Asks Fed. Circ. To Nix Delay Defense In Stent IP Row
- 8th Circ. Revives Medtox Junk Fax Suit
- 2 Biotechs Set Terms On IPOs Totaling $108M
- FDA Warns Abilify Tied To 'Uncontrollable Urges' For Sex, Food
- KaloBios Investor Settlement Hints At Kaye Scholer Suit
- VA Now Open To Non-Trade Agreements Act Compliant Drugs
- Pharma Bad Boy Shkreli May Face Additional Criminal Charges
- Eli Lilly Ducks Suit Over Zyprexa Side Effects
- Allergan, Others Hit With Another Drug Price-Fixing Suit
- Quintiles, IMS Health To Join In $8.9B Merger Of Equals
- Depomed Tells Fed. Circ. AIA Reviews Are Unconstitutional
- Heart Drug IP Relies On Obvious Aspirin Combo, PTAB Told
- Amneal Fights To Maintain Claims In Suboxone MDL
- KaloBios Reaches Deal To End Fight Over $8M Investment
- Lamictal Buyers Ask High Court Not To Take Antitrust Case
- Endo Fights In Fed. Circ. To Keep Opana Painkiller Patents
- Impax Sues Ex-Shkreli Co. For $20M In Daraprim Dispute
- J&J Hit With $55M Verdict In Ovarian Cancer Trial
- TTAB Refuses Mucinex 'Mini Melts' TMs
- Diet Pill Co., Snooki Won't Get 2nd Circ. Input In False Ad Suit
- Judge Slams 'Outrageous' Delay In Settlement Malpractice Row
- Kohlberg Nabs Majority Stake In Spinal Medical Device Maker
- Pioneer Drug For Parkinson's Psychosis Wins FDA Approval
- Class Attys In Vioxx Case Ask For Approval Of $1B Deal